Angus G Jones

List of Publications by Year
in descending order

75 papers	3,366 citations	186265 28 h-index	161849 54 g-index
83 all docs	83 docs citations	83 times ranked	4499 citing authors

#	Article	IF	Citations
1	The clinical utility of Câ€peptide measurement in the care of patients with diabetes. Diabetic Medicine, 2013, 30, 803-817.	2.3	455
2	Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes and Endocrinology,the, 2019, 7, 442-451.	11.4	280
3	The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 2014, 57, 187-191.	6.3	240
4	A Type 1 Diabetes Genetic Risk Score Can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults. Diabetes Care, 2016, 39, 337-344.	8.6	231
5	A reference map of potential determinants for the human serum metabolome. Nature, 2020, 588, 135-140.	27.8	230
6	Specific Câ€Terminal Cleavage and Inactivation of Interleukinâ€8 by Invasive Disease Isolates ofStreptococcus pyogenes. Journal of Infectious Diseases, 2005, 192, 783-790.	4.0	175
7	Markers of Î²-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care, 2016, 39, 250-257.	8.6	132
8	Type 1 diabetes defined by severe insulin deficiency occurs after 30Âyears of age and is commonly treated as type 2 diabetes. Diabetologia, 2019, 62, 1167-1172.	6.3	100
9	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care, 2018, 41, 1844-1853.	8.6	91
10	Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open, 2015, 5, e009088.	1.9	81
11	Adult-Onset Type 1 Diabetes: Current Understanding and Challenges. Diabetes Care, 2021, 44, 2449-2456.	8.6	73
12	Logistic regression has similar performance to optimised machine learning algorithms in a clinical setting: application to the discrimination between type 1 and type 2 diabetes in young adults. Diagnostic and Prognostic Research, 2020, 4, 6.	1.8	69
13	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care, 2018, 41, 705-712.	8.6	67
14	Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010â€“2017. Diabetes, Obesity and Metabolism, 2019, 21, 1576-1584.	4.4	64
15	Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes, Obesity and Metabolism, 2018, 20, 2159-2168.	4.4	63
16	Urine C-Peptide Creatinine Ratio Is a Noninvasive Alternative to the Mixed-Meal Tolerance Test in Children and Adults With Type 1 Diabetes. Diabetes Care, 2011, 34, 607-609.	8.6	62
17	Practical Classification Guidelines for Diabetes in patients treated with insulin: a cross-sectional study of the accuracy of diabetes diagnosis. British Journal of General Practice, 2016, 66, e315-e322.	1.4	60
18	Understanding the manifestation of diabetes in sub Saharan Africa to inform therapeutic approaches and preventive strategies: a narrative review. Clinical Diabetes and Endocrinology, 2019, 5, 2.	2.7	54

#	Article	IF	Citations
19	Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes. Diabetes Care, 2021, 44, 1243-1251.	8.6	52
20	Random nonâ€fasting Câ€“peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabetic Medicine, 2016, 33, 1554-1558.	2.3	50
21	Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18â€“50 years. BMJ Open, 2019, 9, e031586.	1.9	49
22	Sustained influence of metformin therapy on circulating glucagonâ€like peptideâ€1 levels in individuals with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 356-363.	4.4	47
23	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. PLoS Medicine, 2020, 17, e1003149.	8.4	47
24	Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by SLC29A4) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study. Diabetes Care, 2019, 42, 1027-1033.	8.6	43
25	Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Research and Care, 2020, 8, e001238.	2.8	43
26	Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study. Cell Reports Medicine, 2022, 3, 100477.	6.5	39
27	A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibodyâ€“Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy. Diabetes Care, 2019, 42, 208-214.	8.6	35
28	Urine Câ€peptide creatinine ratio is an alternative to stimulated serum Câ€peptide measurement in lateâ€onset, insulinâ€treated diabetes. Diabetic Medicine, 2011, 28, 1034-1038.	2.3	32
29	Persistent Câ€peptide is associated with reduced hypoglycaemia but not HbA_{1c} in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?. Diabetic Medicine, 2019, 36, 1092-1099.	2.3	32
30	Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia, 2018, 61, 66-74.	6.3	30
31	Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?. PLoS ONE, 2016, 11, e0152428.	2.5	26
32	Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration. Journal of Hepatology, 2019, 71, 594-602.	3.7	23
33	The impact of insulin administration during the mixed meal tolerance test. Diabetic Medicine, 2012, 29, 1279-1284.	2.3	19
34	The impact of gender on urine C-peptide creatinine ratio interpretation. Annals of Clinical Biochemistry, 2012, 49, 363-368.	1.6	17
35	TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylureaâ€”a MASTERMIND study protocol. BMJ Open, 2020, 10, e042784.	1.9	17
36	Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study. Diabetes Care, 2021, 44, 511-518.	8.6	16

#	Article	IF	Citations
37	Understanding the pathogenesis of lean non-autoimmune diabetes in an African population with newly diagnosed diabetes. Diabetologia, 2022, 65, 675-683.	6.3	16
38	Histological validation of a type 1 diabetes clinical diagnostic model for classification of diabetes. Diabetic Medicine, 2020, 37, 2160-2168.	2.3	15
39	Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin. BMC Endocrine Disorders, 2012, 12, 6.	2.2	14
40	Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach. Clinical Epidemiology, 2018, Volume 10, 1869-1877.	3.0	14
41	Urinary Câ€peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabetic Medicine, 2013, 30, 1342-1348.	2.3	13
42	Current laboratory requirements for adrenocorticotropic hormone and renin/aldosterone sample handling are unnecessarily restrictive. Clinical Medicine, 2017, 17, 18-21.	1.9	13
43	Identifying Good Responders to Glucose Lowering Therapy in Type 2 Diabetes: Implications for Stratified Medicine. PLoS ONE, 2014, 9, e111235.	2.5	12
44	What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. BMC Medicine, 2019, 17, 79.	5.5	10
45	Effect of the Holiday Season in Patients With Diabetes: Glycemia and Lipids Increase Postholiday, but the Effect Is Small and Transient. Diabetes Care, 2014, 37, e98-e99.	8.6	9
46	Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study. Genome Medicine, 2020, 12, 109.	8.2	8
47	Associations between low HDL, sex and cardiovascular risk markers are substantially different in sub-Saharan Africa and the UK: analysis of four population studies. BMJ Global Health, 2021, 6, e005222.	4.7	8
48	Reevaluation of a case of type 1 diabetes mellitus diagnosed before 6 months of age. Nature Reviews Endocrinology, 2010, 6, 347-351.	9.6	7
49	Comparison of oral glucose tolerance test and ambulatory glycaemic profiles in pregnant women in Uganda with gestational diabetes using the FreeStyle Libre flash glucose monitoring system. BMC Pregnancy and Childbirth, 2020, 20, 635.	2.4	7
50	Mortality amongst children and adolescents with type 1 diabetes in <scp>subâ€Saharan</scp> Africa: The case study of the Changing Diabetes in Children program in Cameroon. Pediatric Diabetes, 2022, 23, 33-37.	2.9	6
51	Diagnosing Type 1 diabetes in adults: Guidance from the UK T1D Immunotherapy consortium. Diabetic Medicine, 2022, 39, e14862.	2.3	6
52	The challenge of diagnosing type 1 diabetes in older adults. Diabetic Medicine, 2020, 37, 1781-1782.	2.3	5
53	Genome-Wide Association Analysis of Pancreatic Beta-Cell Glucose Sensitivity. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 80-90.	3.6	5
54	Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes: a cohort study. BMC Medicine, 2021, 19, 184.	5.5	5

#	Article	IF	Citations
55	HbA1c performs well in monitoring glucose control even in populations with high prevalence of medical conditions that may alter its reliability: the OPTIMAL observational multicenter study. BMJ Open Diabetes Research and Care, 2021, 9, e002350.	2.8	5
56	Phaeochromocytoma. BMJ: British Medical Journal, 2012, 344, e1042-e1042.	2.3	4
57	Zinc transporter 8 autoantibody testing requires age-related cut-offs. BMJ Open Diabetes Research and Care, 2021, 9, e002296.	2.8	4
58	Practical implications of choice of test in National Institute for Health and Clinical Excellence (<scp>NICE</scp>) guidance for the prevention of TypeÂ2 diabetes. Diabetic Medicine, 2013, 30, 126-127.	2.3	3
59	Clusters provide a better holistic view of type 2 diabetes than simple clinical features â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2019, 7, 669.	11.4	3
60	Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus â€“ A MASTERMIND precision medicine approach (UKPDS 87). Diabetes Research and Clinical Practice, 2020, 166, 108333.	2.8	3
61	Dietary metabolite profiling brings new insight into the relationship between nutrition and metabolic risk: An IMI DIRECT study. EBioMedicine, 2020, 58, 102932.	6.1	3
62	A novel case of a raised testosterone and LH in a young man. Clinica Chimica Acta, 2011, 412, 1999-2001.	1.1	2
63	Post-meal Urinary C-peptide creatinine ratio is a moderate measure of insulin secretion in diabetes patients in Cameroon: results from a cross-sectional study. PAMJ Clinical Medicine, 0, 3, .	0.0	2
64	Is glycaemic control associated with dietary patterns independent of weight change in people newly diagnosed with type 2 diabetes? Prospective analysis of the Early-ACTivity-In-Diabetes trial. BMC Medicine, 2022, 20, 161.	5.5	2
65	Continuous glucose monitoring demonstrates low risk of clinically significant hypoglycemia associated with sulphonylurea treatment in an African type 2 diabetes population: results from the OPTIMAL observational multicenter study. BMJ Open Diabetes Research and Care, 2022, 10, e002714.	2.8	2
66	Comment on: â€œDulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A postâ€hoc analysis of the AWARDâ€2, â^'4 and â^'5 trialsâ€. Diabetes, Obesity and Metabolism, 2018, 20, 1549-1550.	4.4	1
67	T-Cell Autoreactivity in Type 2 Diabetes: Benign or Pathogenic, Smoke or Fire?. Diabetes, 2022, 71, 1167-1169.	0.6	1
68	A woman with episodic headaches, sweating, and palpitations. BMJ: British Medical Journal, 2011, 342, d2977-d2977.	2.3	0
69	Preoperative Endocrine Function and Fluid Electrolyte Balance. , 2014, , 95-105.		0
70	Title is missing!. , 2020, 17, e1003149.		0
71	Title is missing!. , 2020, 17, e1003149.		0
72	Title is missing!. , 2020, 17, e1003149.		0

#	Article	IF	Citations
73	Title is missing!. , 2020, 17, e1003149.		0
74	Title is missing!. , 2020, 17, e1003149.		0
75	Islet autoantibody positivity in an adult population with recently diagnosed diabetes in Uganda. PLoS ONE, 2022, 17, e0268783.	2.5	0